fromMedCity News
3 weeks agoBioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute - MedCity News
BioNTech's acquisition of CureVac represents a strategic move to mitigate legal risks while combining their mRNA capabilities to enhance cancer treatment development.
NYC startup